Advertisement

Interactions and Monitoring of Antipsychotic Drugs

  • Christoph HiemkeEmail author
  • Bruno Pfuhlmann
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 212)

Abstract

As a consequence of individualized antipsychotic pharmacotherapy, many patients need more than a single drug, since they do not respond sufficiently to monotherapy. Other patients suffer from comorbid diseases and therefore require additional drugs from other pharmacological classes. Drug combinations, however, can give rise to pharmacokinetic and/or pharmacodynamic drug–drug interactions. Evaluation of pharmacokinetic interactions with antipsychotic drugs must consider substrate, inhibitor, and inducer properties for the cytochrome P450 (CYP) isoenzymes of all combined drugs. For consideration of pharmacodynamic interactions, special attention must be given to effects on dopamine D2, histamine H1, and acetylcholine M1 receptors and on cardiac potassium channels. Additive pharmacological actions of combined drugs on these target structures can induce adverse reactions such as extrapyramidal symptoms, drowsiness, metabolic disturbances leading to weight gain and cardiac problems, cognitive impairment, delirium, or ventricular arrhythmia. Measuring plasma concentrations, i.e., therapeutic drug monitoring (TDM), is valuable to adjust antipsychotic medication when drug combinations contain inhibitors or inducers that alter plasma concentrations of the antipsychotic drugs. Amalgamating the broad knowledge on drug–drug interactions and using appropriately the option to monitor plasma concentrations in blood will help to apply complex combination therapies with antipsychotic drugs with maximal efficiency and safety.

Keywords

Drug–drug interactions Cytochrome P450 Therapeutic drug monitoring Plasma concentration Pharmacokinetics Pharmacodynamics 

References

  1. Baptista T, Zárate J, Joober R, Colasante C, Beaulieu S, Páez X, Hernández L (2004) Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 5:279–299PubMedCrossRefGoogle Scholar
  2. Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25:383–399PubMedCrossRefGoogle Scholar
  3. Bender S, Grohmann R, Engel RR, Degner D, Dittmann Balcar A, Rüther E (2004) Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry 37(1):S46–S53PubMedGoogle Scholar
  4. Benet LZ, Hoener B-A (2002) Changes in plasma binding have little clinical relevance. Clin Pharmacol Ther 71:115–121PubMedCrossRefGoogle Scholar
  5. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27:539–543PubMedCrossRefGoogle Scholar
  6. Cascorbi I (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261–283PubMedCrossRefGoogle Scholar
  7. Castberg I, Skogvoll E, Spigset O (2007) Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 68:1540–1545PubMedCrossRefGoogle Scholar
  8. Chew ML, Mulsant BH, Poloock BG, Lehman ME, Greenspan A, Mahmoud RA, Kirshner MA, Sorisio DA, Bies RR, Gharabawi G (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56:1333–1341PubMedCrossRefGoogle Scholar
  9. Cole ML, Trigoboff E, Demler TL, Opler LA (2010) Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine. J Psychiatr Pract 16:75–81PubMedCrossRefGoogle Scholar
  10. Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM Jr (2006) Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 23:1133–1143PubMedCrossRefGoogle Scholar
  11. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB (2011) Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 90:117–125PubMedCrossRefGoogle Scholar
  12. DeGorter MK, Xia CQ, Yang JJ, Kim RB (2012) Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249–273PubMedCrossRefGoogle Scholar
  13. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604PubMedCrossRefGoogle Scholar
  14. Faber MS, Jetter A, Fuhr U (2005) Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125–134PubMedCrossRefGoogle Scholar
  15. Farde L, Nordström AL, Wiesel F-A, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544PubMedCrossRefGoogle Scholar
  16. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76PubMedCrossRefGoogle Scholar
  17. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26PubMedCrossRefGoogle Scholar
  18. Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106:323–330PubMedCrossRefGoogle Scholar
  19. Ghadirian AM, Annable L, Bélanger MC, Chouinard G (1996) A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 57:22–28PubMedGoogle Scholar
  20. Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O’Keane V, Papakostas G, Vieta E, Zohar J (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 19:520–532PubMedCrossRefGoogle Scholar
  21. Gross G, Drescher K (2012) The role of dopamine D3 receptors for antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments, vol 213, Handbook of Experimental Pharmacology. Springer, BerlinGoogle Scholar
  22. Gründer G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60:974–977PubMedCrossRefGoogle Scholar
  23. Gründer G, Hiemke C, Paulzen M, Veselinovic T, Vernaleken I (2011) Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 44:236–248PubMedCrossRefGoogle Scholar
  24. Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL (2012) In: Gross G, Geyer M (ed) Current antipsychotics. Handbook of Experimental Pharmacology, vol 212. Springer, Berlin, pp xxx–xxxGoogle Scholar
  25. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry—update 2011. Pharmacopsychiatry 44:195–235CrossRefGoogle Scholar
  26. Jecel J, Michel TM, Gutknecht L, Schmidt D, Pfuhlmann B, Jabs BE (2005) Toxic clozapine serum levels during acute urinary tract infection: a case report. Eur J Clin Pharmacol 60:909–910PubMedCrossRefGoogle Scholar
  27. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 33:2303–2312PubMedCrossRefGoogle Scholar
  28. Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368–374PubMedCrossRefGoogle Scholar
  29. Juurlink DN, Mamdani MM, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc 289:1652–1658CrossRefGoogle Scholar
  30. Kannakeril PC, Roden DM (2007) Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 22:39–43CrossRefGoogle Scholar
  31. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553–559PubMedCrossRefGoogle Scholar
  32. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921–928PubMedGoogle Scholar
  33. Kirschbaum KM, Uhr M, Holthoewer D, Namendorf C, Pierzik C, Hiemke C, Schmitt U (2011) Pharmacokinetics of acute and subchronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010(59):474–479Google Scholar
  34. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH (2000) Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504–513PubMedGoogle Scholar
  35. Lee S-O, Kim Y-J, Kim K-T, Choe H, Jo S-H (2006) Blockade of HERG human K+ channels on I Kr of guinea-pig cardiomyocytes by the antipsychotic drug clozapine. Br J Pharmacol 148:499–509PubMedCrossRefGoogle Scholar
  36. Letsas KP, Sideris A, Kounas SP, Efremidis M, Korantzopoulos P, Kardaras F (2006) Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol 109:273–274PubMedCrossRefGoogle Scholar
  37. Lowe EJ, Ackman ML (2010) Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 44:727–732CrossRefGoogle Scholar
  38. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH (2000) Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 61:594–599PubMedCrossRefGoogle Scholar
  39. Lynch T, Price A (2007) The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 76:391–396PubMedGoogle Scholar
  40. Ma X, Idie J, Gonzalez FJ (2008) The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 4:895–908PubMedCrossRefGoogle Scholar
  41. Medori R, Mannaert E, Gründer G (2006) Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16:233–240PubMedCrossRefGoogle Scholar
  42. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, Shida H, Oguchi Y, Okumura Y, Ito O, Kayama H (2011) Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross sectional study. BMC Psychiatry 11:118PubMedCrossRefGoogle Scholar
  43. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2011) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--A systematic review and meta-analysis. Schizophr Bull 2011 [Epub ahead of print]Google Scholar
  44. Moons T, de Roo M, Claes S, Dom G (2011) Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12:1193–1211PubMedCrossRefGoogle Scholar
  45. Nakamura A, Mihara K, Nagai G, Suzuki T, Kondo T (2009) Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit 31:575–578PubMedCrossRefGoogle Scholar
  46. Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(suppl 1):20–27PubMedGoogle Scholar
  47. Nickl-Jockschat T, Paulzen M, Schneider F, Grözinger M (2009) Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol 32(1):55PubMedCrossRefGoogle Scholar
  48. Pang X, Cheng J, Krausz KW, Guo DA, Gonzalez FJ (2011) Pregnane X receptor-mediated induction of Cyp3a by black cohosh. Xenobiotica 41:112–123PubMedCrossRefGoogle Scholar
  49. Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, Deckert J, Jabs B (2009) Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392–394PubMedCrossRefGoogle Scholar
  50. Richelsen E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68:29–39CrossRefGoogle Scholar
  51. Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350(10):1013–1022PubMedCrossRefGoogle Scholar
  52. Roden DM, Viswanthan PC (2005) Genetics of acquired long QT syndrome. J Clin Invest 115:2025–2032PubMedCrossRefGoogle Scholar
  53. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 17:1–13PubMedCrossRefGoogle Scholar
  54. Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283–304PubMedCrossRefGoogle Scholar
  55. Silvestre JS, Prous J (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. J Methods Find Exp Clin Pharmacol 27:289–304CrossRefGoogle Scholar
  56. Sinz M, Wallace G, Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10:391–400PubMedCrossRefGoogle Scholar
  57. Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4–22PubMedCrossRefGoogle Scholar
  58. Spina E, Santoro V, D’Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30:1206–1227PubMedCrossRefGoogle Scholar
  59. Spina E, Scordo MG, D’Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517–538PubMedCrossRefGoogle Scholar
  60. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Härtter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148–153PubMedCrossRefGoogle Scholar
  61. Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503–511PubMedCrossRefGoogle Scholar
  62. Talvik M, Nordstrom AL, Larsen NE, Jucaite A, Cervenka S, Halldin C, Farde L (2004) A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology 175:148–153PubMedCrossRefGoogle Scholar
  63. Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM, Amankwa K, Borzak S, Kingery JR, Coram R, Zipes DP, Flockhart DA, Kovacs RJ (2011) Enhanced sensitivity to drug-induced QT interval lenthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol 70:16–23Google Scholar
  64. Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31:7–20PubMedCrossRefGoogle Scholar
  65. Unterecker S, Warrings B, Deckert J, Pfuhlmann B (2012) Correlation of QTc interval-prolongation and serum level of citalopram after intoxication – a case report. Pharmacopsychiatry 45:30–34PubMedCrossRefGoogle Scholar
  66. van Noord C, Eijgelsheim M, Stricker BH (2010) Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 70:16–23PubMedCrossRefGoogle Scholar
  67. Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de pointes. Dtsch Ärztebl Int 108:687–693PubMedGoogle Scholar
  68. Wong DF, Gründer G, Brasic JR (2007) Brain imaging research: does the science serve clinical practice? Int Rev Psychiatry 19:541–558PubMedCrossRefGoogle Scholar
  69. Zhou SF (2009) Polymorphims of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48:761–804PubMedCrossRefGoogle Scholar
  70. Zhu BT (2010) On the general mechanism of selective induction of cytochrome P450 enzymes by chemicals: some theoretical considerations. Expert Opin Drug Metab Toxicol 6:483–494PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Psychiatry and PsychotherapyUniversity Medical Center MainzMainzGermany
  2. 2.Department of Psychiatry, Psychotherapy and PsychosomaticsUniversity Hospital of WürzburgWürzburgGermany

Personalised recommendations